Brokerages Set Kailera Therapeutics, Inc. (NASDAQ:KLRA) Price Target at $42.75

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $42.75.

Several equities analysts have issued reports on KLRA shares. Weiss Ratings initiated coverage on Kailera Therapeutics in a report on Friday, August 14th. They set a “sell (d)” rating on the stock. Wall Street Zen downgraded shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Kailera Therapeutics Stock Performance

KLRA stock opened at $12.70 on Monday. The company has a market cap of $1.65 billion and a price-to-earnings ratio of -0.00. The stock has a 50-day simple moving average of $17.35. Kailera Therapeutics has a 1-year low of $12.47 and a 1-year high of $28.23.

Kailera Therapeutics (NASDAQ:KLRA) last announced its earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.35). On average, equities analysts forecast that Kailera Therapeutics will post -3.89 earnings per share for the current year.

Institutional Investors Weigh In On Kailera Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in KLRA. Tidal Investments LLC purchased a new position in Kailera Therapeutics during the 2nd quarter worth $309,000. Squarepoint Ops LLC purchased a new position in shares of Kailera Therapeutics in the 2nd quarter worth approximately $993,000. Frazier Life Sciences Management L.P. bought a new position in shares of Kailera Therapeutics in the second quarter valued at approximately $24,233,000. Wellington Management Group LLP purchased a new stake in shares of Kailera Therapeutics during the second quarter valued at approximately $64,308,000. Finally, Atlas Venture Life Science Advisors LLC bought a new stake in Kailera Therapeutics during the second quarter worth $113,923,000.

About Kailera Therapeutics

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company’s operations are centered on the development of therapies for global markets.